ÂÜÀòÂÒÂ×

Ziyou Cui has over fifteen years of experience in the biotechnology and pharmaceutical industry. From 2005 to 2009, Cui served as a PhD candidate at the Institute of Biophysics, Chinese Academy of Science, where they developed quantitative methods for protein modification and worked with HPLC, LC-MS/MS, Q-TOF-MS, and MALDI-TOF-MS. From 2009 to 2011, Cui was the Chief Scientist of Mass Spectrometry at the Proteomics Lab and Tianjin Key Laboratory for Prevention and Control of Occupational and Environmental Diseases, where they set up the proteomics platform and conducted research on disease proteomics, quantitative proteomics, and function proteomics. From 2011 to 2014, Cui was a Postdoctoral Associate at the University of California, Davis, where they investigated the function of ubiquitin proteasome system (UPS) in skeletal muscle differentiation. From 2014 to 2017, Cui was a Postdoc Associate/Research Scientist at the University of Minnesota, Twin Cities, focusing on proteomics, protein-protein interaction, protein/DNA adducts, and protein characterization by Mass spectrometry. Since 2017, Cui has been working at Eureka Therapeutics, Inc. in various roles, including Associate Director, Principal Scientist, and Research Scientist III & Project Leader. In these roles, Cui has been heavily involved in a series of the pipeline development of TCR-mimic/CAR-T cell therapy for solid tumors, supervising and coordinating protein (antibody) production, providing bioanalytical insights to multidisciplinary project teams, and mentoring junior scientists.

Ziyou Cui completed a Doctor of Philosophy (PhD) in Proteomics at the Biophysics Institute, Chinese Academy of Sciences from 2005 to 2009. Prior to that, they obtained a Master of Science (MS) in Tumor Immunology and Pathophysiology from the Medical School at Zhengzhou University from 2002 to 2005.